The treatment of psoriasis using fumaric esters is efficient, as shown
by long-term, uncontrolled observations [3, 7] as well as in randomiz
ed, double-blind, placebo-controlled studies [2, 10, 11, 12]. The effi
cacy probably is due to an immunosuppressive effect on T-lymphocytes a
nd cytokines. Unwanted effects have been observed as flush, nausea and
diarrhea as well as hematologic and renal alterations. The present, p
rospective study analyses possible renal side effects systematically.
42/47 patients were observed more than 3 to 70 months (mean 16,5 mo) w
ithout changing their renal retention parameters. However, 21/42 patie
nts revealed altered urinary proteins: a micromolecular tubular protei
nuria developed from a physiological status in 12/21, from a pre-exist
ing pathological status in 8/21 patients. A macromolecular glomerular
proteinuria has been found in only 1/21 patients after therapy, but tr
ansiently in further 4 out of the 12/21 patients with initial tubular
damage. In all but 2/21 patients alterations disappeared within 6 mont
hs. A high daily and cumulative dose of fumaric esters was associated
with tubular damage. The transient tubular resorption defect in 21/42
patients was not accompanied by reduction of the glomerular filtration
rate. However, by additional tubular hazards (infections, toxic hypov
olemia drugs etc.) an acute kidney failure might occur. The analysis o
f a tubular parameter (SDS-PAGE, alpha(1)- or beta(2)-microglobulin) d
uring treatment is recommended.